I’m 66 with more than 80% of my portfolio in cash. I feel like I’m not savvy enough to invest.

You need to look at your overall financial situation to figure out the best plan for your future.

The Fed’s rate cuts were supposed to make borrowing cheaper. So why is it harder than ever to buy a house?

The Federal Reserve’s interest-rate cuts have done little to help home buyers and sellers.

Meme stocks were fueled by Roaring Kitty and ‘Trump trades’ this year. What can we expect in 2025?

The return to social media of Keith Gill, also known as Roaring Kitty, thrust original meme stocks AMC and GameStop back into the spotlight in 2024.

This fund has a 20-year record of success and 7.5% income yield — using options

This income approach has also ridden along with the market’s largest tech gainers.

Hedge fund strategist flags biggest concern for markets in 2025 — and offers ideas for shelter

Ed Cole, head of multi strategy, equities at Man Group talks inflation risks and the problem with investors all in on the U.S. market.

Market timers have given up on stocks — which is exactly what you want to see

There are hopeful signs in the short term, but the longer-term picture for stocks is troubling.

DJT stock drops as Trump moves his entire $4 billion stake into a revocable trust

Trump Media & Technology Group Corp.’s stock fell about 6% in premarket trading on Friday after Donald J. Trump transferred his entire $4 billion stake in the company into a revocable trust, according to filings.

U.S. bitcoin reserve keeps gaining momentum. Will it power crypto’s next rally?

Dennis Porter is now seeing the culmination of years of hard work and his single-minded dedication to the idea that bitcoin can serve as a national strategic asset.

Oil prices head for weekly losses on strong dollar, China demand worries

Oil futures fell Friday and were on track for weekly losses, after feeling pressure from a surging U.S. dollar and continued concerns about the demand outlook, particularly from China, the world’s largest crude importer.

Novo Nordisk’s new weight-loss drug works better, but not as well as expected

Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.